PTC Therapeutics

Spinal Muscular Atrophy Treatment Market Report 2022: Continued Product Approvals Bolsters 18.6% Annual Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 29, 2022
Health, Pharmaceutical, Clinical trial, Ageing, SMA, Gene therapy, EC, UNC Medical Center, Administration, Food, Therapy, Spinal muscular atrophy, Research, Genentech, Royal commission, USD, Disease, Growth, Patient, Novartis, MAP, Treatment, Route of administration, European Commission, Segmental analysis (biology), Food and Drug Administration, EMA, Diagnosis, PTC Therapeutics, Medical device, Pharmaceutical industry, Medical imaging, Coal, Nusinersen, Onasemnogene abeparvovec, Risdiplam

The global spinal muscular atrophy treatment market size is expected to reach USD 18.0 billion by 2030.

Key Points: 
  • The global spinal muscular atrophy treatment market size is expected to reach USD 18.0 billion by 2030.
  • In March 2021, PTC Therapeutics, Inc., received marketing approval for Evrysdi (risdiplam) from the EMA for the treatment of patient with type1, 2, and 3 spinal muscular atrophy.
  • Thus, increasing number of product approvals is expected to drive the spinal muscular atrophy treatment market.
  • For instance, in July 2021, F. Hoffmann-La Roche Ltd launched Evrysdi (risdiplam) for the treatment of patient with spinal muscular atrophy in India
    Chapter 4 Global Spinal Muscular Atrophy Treatment Market - Segment Analysis, By Type, 2018 - 2030 (USD Million)
    Chapter 5 Global Spinal Muscular Atrophy Treatment Market - Segment Analysis, by Treatment, 2018 - 2030 (USD Million)
    Chapter 6 Global Spinal Muscular Atrophy Treatment Market - Segment Analysis, By Drug, 2018 - 2030 (USD Million)
    Chapter 7 Global Spinal Muscular Atrophy Treatment Market - Segment Analysis, by Route of Administration, 2018 - 2030 (USD Million)
    Chapter 8 Spinal Muscular Atrophy Treatment Market: Segment Analysis, by Region, 2018 - 2030 (USD Million)
    Chapter 9 Global Spinal Muscular Atrophy Treatment Market: Competitive Analysis

PTC Therapeutics to Participate at 41st Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, January 4, 2023
PTC Therapeutics, Conference, Therapy, PTC, EST, Pharmaceutical industry, Online shopping

SOUTH PLAINFIELD, N.J., Jan. 4, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Monday, Jan. 9, at 7:30 a.m. PST/10:30 a.m. EST.

Key Points: 
  • SOUTH PLAINFIELD, N.J., Jan. 4, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Monday, Jan. 9, at 7:30 a.m. PST/10:30 a.m. EST.
  • The presentation will be webcast live on the Events and Presentations page under the Investor section of PTC Therapeutics' website at https://ir.ptcbio.com/events-presentations and will be archived for 30 days following the presentation.
  • It is recommended that users connect to PTC's website several minutes prior to the start of the webcast to ensure a timely connection.

hC Bioscience Appoints Martin Maier, Ph.D. To its Scientific Advisory Board; Brings Expertise in Therapeutic Nucleic Acid Development and Delivery

Retrieved on: 
Wednesday, December 7, 2022
Disease, SAB, United States Air Force Scientific Advisory Board, Mutation, PTC Therapeutics, RNA transfection, Therapy, Patient, Medical device, Telescopic sight, Vaccine

Cambridge, Massachusetts--(Newsfile Corp. - December 7, 2022) - hC Bioscience, Inc., a pioneer in the development of tRNA-based therapeutics, appointed Martin Maier, Ph.D., to its Scientific Advisory Board.

Key Points: 
  • Cambridge, Massachusetts--(Newsfile Corp. - December 7, 2022) - hC Bioscience, Inc., a pioneer in the development of tRNA-based therapeutics, appointed Martin Maier, Ph.D., to its Scientific Advisory Board.
  • Dr. Maier's background will bring, among other contributions, an expertise in nucleic acid chemistry and delivery, and the development of nucleic acid therapeutics.
  • hC Bioscience names Martin Maier, Ph.D., to its Scientific Advisory Board.
  • Dr. Maier's background will bring an expertise in nucleic acid chemistry and delivery, and the development of nucleic acid therapeutics.

Moore Kuehn, PLLC Encourages Investors of PTC Therapeutics, Inc. to Contact Law Firm

Retrieved on: 
Thursday, December 15, 2022
PLLC, Telephone, Therapy, Wall Street, Fraud, PTC Therapeutics, Security (finance)

NEW YORK, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of PTC Therapeutics, Inc. (NASDAQ: PTCT) breached their fiduciary duties to shareholders.

Key Points: 
  • NEW YORK, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of PTC Therapeutics, Inc. (NASDAQ: PTCT) breached their fiduciary duties to shareholders.
  • If you own PTCT please contact Justin Kuehn, Esq. by email at [email protected] or telephone at (212) 709-8245.
  • Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
  • Moore Kuehn is a 5-star Google client-rated New York City law firm with attorneys representing investors and consumers in litigation involving securities laws, fraud, breaches of fiduciary duties, and other claims.

Spinal Muscular Atrophy Treatment Market Size, Share & Trends Analysis Report By Type, By Treatment, By Drug, By Route Of Administration, By Region And Segment Forecasts, 2022 - 2030

Retrieved on: 
Thursday, December 15, 2022
Therapy, Spinal muscular atrophy, Ageing, SMA, Food, Gene therapy, UNC Medical Center, MAP, EC, Diagnosis, Royal commission, EMA, Patient, Treatment, Authorization, Research, Genentech, Disease, European Commission, Route of administration, PTC Therapeutics, Food and Drug Administration Safety and Innovation Act, Growth, Clinical trial, Novartis, USD, Medical device, Pharmaceutical industry, Nusinersen, Onasemnogene abeparvovec, Risdiplam

View original content:https://www.prnewswire.com/news-releases/spinal-muscular-atrophy-treatme...

Key Points: 
  • Spinal Muscular Atrophy Treatment Market Size, Share & Trends Analysis Report By Type (Type1, Type 2), By Treatment (Gene Therapy, Drug), By Drug (Spinraza, Zolgensma), By Route Of Administration, By Region, And Segment Forecasts, 2022 - 2030
    The global spinal muscular atrophy treatment market size is expected to reach USD 18.0 billion by 2030.
  • In March 2021, PTC Therapeutics, Inc., received marketing approval for Evrysdi (risdiplam) from the EMA for the treatment of patient with type1, 2, and 3 spinal muscular atrophy.
  • Thus, increasing number of product approvals is expected to drive the spinal muscular atrophy treatment market.
  • For instance, in July 2021, F. Hoffmann-La Roche Ltd launched Evrysdi (risdiplam) for the treatment of patient with spinal muscular atrophy in India
    ReportLinker is an award-winning market research solution.

BioNJ Hosts Its Inaugural Health Equity in Clinical Trials MBA Business Plan Case Competition

Retrieved on: 
Tuesday, December 6, 2022
Baylor College of Medicine, Therapy, Rare disease, Alzheimer's disease, Advocacy, Business school, Clinical trial, Johns Hopkins University, Ecosystem, Public policy, Rutgers Business School – Newark and New Brunswick, Sharon Wyatt, Science, Conference, Bristol Myers Squibb, Thermo Fisher Scientific, PTC, Inclusion, Committee, Student, Population health, Third place, Psychology, Government, Health equity, Patient, PTC Therapeutics, Enrollment, Rice University, Senior, Second Place, Safety, Head, Prostate cancer, First Place, United States Navy Special Projects Office, Sanofi, Organization, Pharmaceutical industry, Management, Medicine, Medidata Solutions

TRENTON, N.J., Dec. 6, 2022 /PRNewswire/ -- BioNJ, New Jersey's life sciences trade association, hosted an Inaugural Health Equity in Clinical Trials MBA Business Plan Case Competition on Saturday, December 3, at Rutgers Business School. BioNJ's Business Plan Case Competition, which is part of a broader BioNJ strategic initiative of Health Equity in Clinical Trials, was designed to promote the next generation of diverse clinical trial innovators and identify innovative approaches and successful models that can be used nationally to strengthen diversity in clinical trials and expand health equity.

Key Points: 
  • "Only by improving diversity in clinical trials will we be able to deepen our understanding of the safety and efficacy of medicines for all populations.
  • Each of the business plans offered a unique out-of-the-box solution helping advance our ambition to have no Patient left behind."
  • Second Place: Rutgers Business School ($7,000) who focused their plan on using population health and real-world data analytics to calculate health equity targets specific to clinical trial sites in prostate cancer.
  • It is with the vision ofHealthEquity for all thatBioNJ launched our Health Equity in Clinical Trials Strategic Initiative, of which the MBA Business Plan Competition is one of three important workstreams," saidBioNJ President and CEO, Debbie Hart.

Brazilian Regulatory Authority Grants Approval for Waylivra™ for Familial Partial Lipodystrophy

Retrieved on: 
Thursday, December 1, 2022
Abdominal pain, FPL, Enzyme replacement therapy, European Medicines Agency, PTC Therapeutics, Union, Pancreatitis, TG, Triglyceride, Chylomicron, Risk, Liver disease, Insulin resistance, Anovulation, Therapy, Hypertriglyceridemia, Cognition, Brain, ANVISA, Patient, HTG, Anxiety, Diet, Brazilian Health Regulatory Agency, Disease, Adipose tissue, Diabetes, Acute pancreatitis, Depression, Cirrhosis, FCS, Dyslipidemia, Hyperandrogenism, Quality of life, PTC, Lipoprotein lipase deficiency, Woman, LPL, Liver, Pharmaceutical industry, Medical imaging, Volanesorsen, Ionis

SOUTH PLAINFIELD, N.J., Dec. 1, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Brazilian Health Regulatory Agency, ANVISA (Agência Nacional de Vigilância Sanitária), has approved Waylivra™ (volanesorsen) as the first treatment for familial partial lipodystrophy (FPL) in Brazil. This is the first approval globally for Waylivra for the FPL indication. Waylivra is also approved in Brazil for the treatment of Familial Chylomicronemia Syndrome (FCS).

Key Points: 
  • SOUTH PLAINFIELD, N.J., Dec. 1, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Brazilian Health Regulatory Agency, ANVISA (Agncia Nacional de Vigilncia Sanitria), has approved Waylivra (volanesorsen) as the first treatment for familial partial lipodystrophy (FPL) in Brazil.
  • This is the first approval globally for Waylivra for the FPL indication.
  • Waylivra is also approved in Brazil for the treatment of Familial Chylomicronemia Syndrome (FCS).
  • ANVISA's approval for Waylivra for FPL was based on results from the Phase 2/3 BROADEN study in patients with familial partial lipodystrophy.

ClearPoint Neuro Reports Third Quarter 2022 Results

Retrieved on: 
Tuesday, November 8, 2022
Quality of life, GLOBE, Investment, PTC, U.S. Securities and Exchange Commission, Nasdaq, Paper, Telephone, Research, BD (company), European Commission, COVID-19, Therapy, Brain, Solution, Particular, Software, Royal commission, Company, Product, PTC Therapeutics, Patient, Growth, CEO, Security (finance), History, CNS, FDA, Biopsy, Video game, Pharmaceutical industry, Medical device, Renewable energy

SOLANA BEACH, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the Company), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its third quarter ended September30, 2022.

Key Points: 
  • SOLANA BEACH, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the Company), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its third quarter ended September30, 2022.
  • Upstaza will be administered with the Companys SmartFlow Neuro Cannula;
    Added multiple new biologics and drug delivery partners in the quarter to bring the total to approximately 50;
    Announced multiple FDA clearances: the ClearPoint Maestro Brain Model, the ClearPoint Prism Neuro Laser Therapy System and the 2.1 version of the ClearPoint Neuro Navigation software; and
    Cash and short-term investments totaled $40.5 million as of September30, 2022.
  • We achieved another strong quarter for revenue despite a historically high case cancellation rate and hospital supply chain disruptions.
  • Operating expenses for the third quarter of 2022 were $7.5 million, compared to $6.8 million for the third quarter of 2021.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

Retrieved on: 
Monday, November 7, 2022
GLOBE, PTC Therapeutics, Pomerantz, PTC, Company, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, NASDAQ, News, State, Private investigator

NEW YORK, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (PTC or the Company) (NASDAQ:PTCT).

Key Points: 
  • NEW YORK, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (PTC or the Company) (NASDAQ:PTCT).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether PTC and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Medidata Gathers Life Sciences Leaders to ‘Solve Their Impossible’ at NEXT New York Conference

Retrieved on: 
Monday, November 7, 2022
Technology, Research, Other Technology, Clinical Trials, Software, Biotechnology, Health, Data Management, Science, Cloud, LabCorp, DCT, Euronext Paris, PTC Therapeutics, Knowledge, Digital, EHR, Medical device, Real, Bristol Myers Squibb, EDC, Same language subtitling, Clinical trial, Industry, Precision medicine, Memory, Benefit, CATIA, Health, Language, Dassault Group, DELMIA, Medical imaging, Vaccine, Life cycle, ICON, Data management, 3D, Learning, Artificial intelligence, PPD, Syneos Health, Development, Therapy, Life, Patient, Association, Next, Health care, Equitable, SIMULIA, SOLIDWORKS, Johnson & Johnson, CTI, Research, Clinical data management, Pharmaceutical industry, Music, Chilukuri Narayana Rao, Medidata Solutions, Compass, BIOVIA, Parexel, GEOVIA, ENOVIA

NEXT New York, November 15-16, will feature interactive experiences along with provocative discussions of the leading issues in clinical trial research.

Key Points: 
  • NEXT New York, November 15-16, will feature interactive experiences along with provocative discussions of the leading issues in clinical trial research.
  • Life sciences most innovative thinkers have been invited to Come Solve Your Impossible and enable tomorrows breakthroughs.
  • NEXT New York will be an experience like no other event in life sciences.
  • Medidata is leading the digital transformation of life sciences, creating hope for millions of patients.